What Is GHRP-2? Benefits, Research & Safety
A potent growth hormone-releasing peptide that stimulates GH secretion through the ghrelin receptor, with additional effects on appetite and cortisol.
UK summary: Not a licensed UK medicine. Growth-hormone-releasing peptide. Prohibited at all times under WADA S2. Sometimes used in clinical research diagnostically (GH-stimulation testing), not as a therapy.
Quick Facts
Overview
GHRP-2 — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. Growth-hormone-releasing peptide. Prohibited at all times under WADA S2. Sometimes used in clinical research diagnostically (GH-stimulation testing), not as a therapy.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not licensed for human use. Research compound only.
- EU: Not approved for therapeutic use.
- Notes: GHRP-2 is approved in Japan as a diagnostic agent (Pralmorelin). It is not approved therapeutically anywhere. Prohibited in sports by WADA.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Restores youthful GH levels safely.
- Effective treatment for sarcopenia or adult GH deficiency.
- Undetectable by WADA testing.
- Safe for daily long-term use.
07Common internet claims
- Marketed as a cleaner alternative to HGH for body composition.
- Sold by online retailers for stacking with CJC-1295.
- Promoted by 'anti-ageing' clinics for off-label use.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Used in NHS GH diagnostic testing — therefore safe” | C | Yes | High | GHRP-2 has a research / diagnostic history; that does not equate to a licensed therapy for healthy adults. |
| “Effective and safe long-term” | E | No | High | Long-term safety data in healthy adults is limited. |
| “Permitted for non-tested athletes” | E | No | High | Prohibited at all times under WADA S2; strict-liability rules apply regardless of testing schedule. |
09Safety uncertainty score
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Cortisol and prolactin elevation (unlike Ipamorelin).
- Water retention, joint pain, carpal tunnel symptoms (GH-axis effects).
- Injection-site reactions.
- Theoretical oncologic risk from sustained IGF-1 elevation.
11Drug-interaction uncertainty
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
13UK legal position
Not licensed for human use. Research compound only.
14EU legal position
Not approved for therapeutic use.
15What this page cannot tell you
- Whether a UK-purchased vial contains GHRP-2 at the labelled concentration.
- How sustained cortisol elevation affects metabolic and immune outcomes.
- What the cancer risk profile is over years of off-label use.
- Whether it triggers WADA detection — assume yes, prohibition is strict-liability.
16Last reviewed
17Citation quality score
18Research gaps
- Diagnostic-test use does not translate to licensed therapeutic indication.
- Long-term outcome data in healthy adults absent.
- Combination-stack safety with CJC-1295, Ipamorelin uncharacterised.
- Cancer surveillance data unavailable.
19Safer alternatives / established care pathways
- Endocrinologist review with ITT or GHRH-arginine testing if adult GH deficiency is clinically suspected.
- Licensed recombinant HGH (Genotropin, Norditropin) under specialist supervision where genuine deficiency is confirmed.
- Resistance training and protein-adequate nutrition for body-composition goals.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is GHRP-2 a licensed UK medicine?
- What's the WADA / UKAD position?
- What licensed treatments exist for the underlying issue?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Potent growth hormone release from the pituitary
- 2Elevated IGF-1 levels
- 3Potential improvements in body composition
- 4Possible enhancement of recovery and tissue repair
- 5Appetite stimulation (may benefit those needing to gain weight)
- 6Synergistic effects with GHRH analogues
Claim vs Evidence
How popular claims about GHRP-2 stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Used in NHS GH diagnostic testing — therefore safe” | C | Yes | High | GHRP-2 has a research / diagnostic history; that does not equate to a licensed therapy for healthy adults. |
| “Effective and safe long-term” | E | No | High | Long-term safety data in healthy adults is limited. |
| “Permitted for non-tested athletes” | E | No | High | Prohibited at all times under WADA S2; strict-liability rules apply regardless of testing schedule. |
Theoretical Dosing & Protocols
| Theoretical Dosage | 100-300 mcg per dose |
| Frequency | 2-3 times daily, typically before meals and at bedtime |
| Duration | Variable; often cycled |
| Notes | GHRP-2 is not approved for therapeutic use outside diagnostic applications. It causes more cortisol/prolactin release than Ipamorelin and more appetite stimulation. Any use should be under medical supervision. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (most common)
- Intravenous (diagnostic use)
| Half-Life | Stability |
|---|---|
| Approximately 25-30 minutes | Lyophilised powder stable when properly stored; reconstituted solution should be refrigerated |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Increased appetite
- Water retention
- Injection site reactions
- Flushing
- Tingling or numbness
- Transient cortisol elevation
Rare Risks & Concerns
- Prolonged effects on cortisol with chronic use
- Potential effects on glucose metabolism
- Unknown long-term effects
- Theoretical concerns with tumour growth
Contraindications
- Active malignancy
- Pregnancy and breastfeeding
- Diabetes (monitor closely)
- Conditions exacerbated by cortisol elevation
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for human use. Research compound only.
🇪🇺 European Union
Not approved for therapeutic use.
Clinical Studies Summary
GHRP-2 as a GH Secretagogue
Research characterising GHRP-2's GH-releasing properties and effects on other hormones.
Looking for GHRP-2?
Source research-grade GHRP-2 from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about GHRP-2
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is GHRP-2 a licensed UK medicine?
- What's the WADA / UKAD position?
- What licensed treatments exist for the underlying issue?
UK regulatory & safety context
Related Research Guides
Peptide Comparisons
Related Peptides
CJC-1295
A synthetic growth hormone-releasing hormone analogue designed for extended half-life and sustained growth hormone secretion.
Learn moreIpamorelin
A selective growth hormone-releasing peptide known for its favourable side effect profile, stimulating GH release without significantly affecting cortisol or prolactin.
Learn moreGHRP-6
The first clinically evaluated growth hormone-releasing peptide, notable for its potent GH release and pronounced appetite-stimulating effects.
Learn moreHexarelin
A potent growth hormone-releasing peptide with notable cardioprotective properties independent of GH release.
Learn more